ABSTRACT: The use of radiation as adjuvant therapy for patients with cutaneous malignant melanoma has been hindered by the unsubstantiated belief that melanoma cells are radioresistant. An abundance of literature has now demonstrated that locoregional relapse of melanoma is common after surgery alone when certain clinicopathologic features are present. Features associated with a high risk of primary tumor recurrence include desmoplastic subtype, positive microscopic margins, recurrent disease, and thick primary lesions with ulceration or satellitosis. Features associated with a high risk of nodal relapse include extracapsular extension, involvement of four or more lymph nodes, lymph nodes measuring at least 3 cm, cervical lymph node location, and recurrent disease. Numerous studies support the efficacy of adjuvant irradiation in these clinical situations. Although data in the literature remain sparse, evidence also indicates that elective irradiation is effective in eradicating subclinical nodal metastases after removal of the primary melanoma. Consequently, there may be an opportunity to integrate radiotherapy into the multimodality treatment of patients at high risk of subclinical nodal disease, particularly those with an involved sentinel lymph node. Such patients are known to have a low rate of additional lymph node involvement, and thus in this group, a short course of radiotherapy may be an adequate substitute for regional lymph node dissection. This will be the topic of future research.
Because of improved public awareness, most cases of cutaneous malignant melanoma are diagnosed at an early stage and can be cured by simple surgical resection. Local recurrence after wide local excision of primary disease is rare, and with few exceptions, the role of adjuvant local therapy in primary melanoma is limited. As the thickness of the primary melanoma increases, however, so does the risk of lymphatic spread. Surgical resection of clinically documented regional disease results in satisfactory regional control, but for certain patients adjuvant regional irradiation is indicated to prevent potentially morbid regional relapse.
For patients without clinically apparent lymphatic involvement, the risk of subclinical nodal disease may be predicted from clinicopathologic features of the primary lesion. In patients with a high risk of subclinical regional disease, approaches have included observation of the nodal basin (with delayed dissection as needed), elective lymph node dissection, and, less frequently, elective lymph node irradiation.
Although elective treatment results in lower rates of nodal recurrence, findings in the four randomized trials investigating the effect of elective dissection on overall survival were negative.[ 1-4] Despite these results, recent developments in sentinel lymph node biopsy techniques have renewed interest in regional lymph node dissection. Patients with an involved sentinel lymph node generally undergo completion dissection. The role of ra diotherapy after sentinel lymph node biopsy remains largely undefined.
In this article we review the rationale and indications for radiotherapy in cutaneous malignant melanoma. We focus first on adjuvant irradiation of the primary tumor site or regional lymph node basins after surgical excision of the primary tumor or dissection of lymph nodes. We then turn to the evolving role of elective nodal irradiation for patients with clinically node-negative disease but a high risk of subclinical nodal involvement. Finally, we discuss the implications of recent developments in sentinel lymph node biopsy for the use of elective lymph node treatment.
Adjuvant Irradiation of the Primary Site
Surgical resection remains the primary mode of therapy for cutaneous malignant melanoma. In general, local recurrence after adequate wide local excision of primary tumors is rare, occurring in fewer than 5% of cases. As detailed in Table 1, the rate of local recurrence is higher when primary lesions are thicker than 4 mm, are located on the head or neck, or are associated with ulceration or satellitosis.[2,5-17]
Even when these factors are present, however, the rate of local recurrence is generally less than 15%, although combinations of these factors- such as thickness greater than 4 mm with ulceration or head and neck location-most likely further increase the risk of local recurrence.[ 6,14] Desmoplastic melanoma, a rare variant of cutaneous melanoma, is associated with a clearly increased local recurrence rate.[18-23] These tumors typically present in elderly patients, have a predilection for head and neck sites, and are associated with perineural invasion. Recurrence rates as high as 50% have been reported after ostensibly adequate wide local excision of desmoplastic melanomas (Table 1).
Adjuvant Radiotherapy Data
Few series have examined the use of adjuvant irradiation of the primary tumor site in the presence of high-risk clinicopathologic features. The first report of this approach was that of Dickson, who analyzed outcomes in a series of 234 patients according to primary treatment. Treatment consisted of local excision alone (71 patients), radical surgery alone (42 patients), or surgery followed by adjuvant radiotherapy (121 patients). In the adjuvant radiotherapy group, surgery usually involved only simple excision or electrocautery. Radium (surface molds or teleradium therapy) or orthovoltage x-rays were used with almost equal frequency-the latter to deliver a dose of 5,000 cGy in 10 days to the primary tumor site. Although the result in terms of local disease control was not reported, overall survival after simple excision and radio- therapy was similar to that after wide local excision and skin grafting.
Johanson et al reported on a group of 54 patients who underwent surgery and radiotherapy for nodular melanoma to a total dose of 24 Gy in three fractions delivered on days 0, 7, and 21. Of the nine patients who received radiotherapy to the primary tumor site for gross or microscopic residual disease, only one developed progressive local disease.
Although prospective studies are lacking, the available data support a strategy of adjuvant irradiation when local recurrence is of concern. Indications for irradiation of the primary tumor site are detailed in Table 2 and include desmoplastic melanoma, but primary thick primary tumors with associated ulceration or satellitosis, close or positive resection margins where re-resection might compromise cosmesis, and locally recurrent disease are also associated with an increased local failure rate and adjuvant irradiation may be warranted. The primary tumor site may also be irradiated when features of the primary tumor by themselves do not indicate the need for local adjuvant irradiation but regional nodal irradiation is indicated (see below).
Adjuvant Irradiation of the Regional Lymph Nodes
For patients who present with documented nodal disease or nodal recurrence after local excision of primary melanoma, therapeutic nodal dissection results in regional control in more than 85% of patients overall. However, several features (Table 3) substantially decrease this satisfactory nodal control rate and indicate a need for adjuvant radiotherapy to avoid uncontrolled regional recurrence. In most series, the presence of any one of these high-risk features results in a 30% to 50% rate of subsequent nodal recurrence after surgery alone.
Although these high-risk features also predict for increased rates of hematogenous metastases, the importance of maintaining regional control and avoiding unmanageable regional recurrence should not be underestimated. The most consistently reported high-risk feature is extracapsular extension, but other factors must also be considered when patients are evaluated for adjuvant therapy.
• Extracapsular Extension—In an early surgical series from M. D. Anderson Cancer Center that included 1,001 patients with nodal metastasis, the nodal failure rate after surgery alone was significantly higher when lymph nodes were described as matted (eg, gross extracapsular extension).[ 26] Investigators from Roswell Park Cancer Institute also reported a significantly elevated regional failure rate in the presence of extracapsular extension. In their series of 338 patients, the nodal failure rate was 63% when extracapsular extension was noted microscopically. This association remained significant on multivariate analysis. In another series, from the John Wayne Cancer Institute, extracapsular extension was the single most important predictor of subsequent regional failure after surgery alone. Reported rates of regional failure after surgery alone for nodal metastases with associated extracapsular extension range from 31% to 63% (Table 3).[26-29]
• Number of Involved Nodes—Another factor associated with an increased risk of regional recurrence is a high number of involved lymph nodes. Lee and colleagues reported regional recurrence rates of 25% when 1 to 3 nodes were involved, 46% for 4 to 10 involved nodes, and 63% for more than 10 involved nodes (P = .0001). Two additional series also revealed an increasing risk of regional recurrence with an increasing number of involved lymph nodes.[28,30] Reported rates of regional failure increase rapidly when four or more lymph nodes are involved, ranging from 22% to 63% (Table 3). Although not specifically addressed in most studies, it is reasonable to predict a high correlation between a high number of positive nodes and the presence of extracapsular extension.
• Size of Lymph Nodes—Lymph node size has less frequently been cor- related with the rate of recurrence, but Lee and colleagues did report higher regional recurrence rates with larger lymph nodes: 25% when lymph nodes were smaller than 3 cm, 42% when they were 3 to 6 cm, and 80% when they were larger than 6 cm (P < .001). This finding is not surprising, as the probability of extracapsular extension generally increases with increasing nodal size.
• Clinical Factors—Finally, clinical factors may also predict an increased rate of regional recurrence. At least two series have reported that nodal recurrence rates are higher for cervical nodal disease than for disease in the axillary or inguinal basins.[ 27,31] Also, some series have suggested that the risk of regional recurrence is higher in patients who undergo therapeutic dissection for clinically apparent disease than in patients who have subclinical nodal metastases discovered at the time of elective dissection.
Specifically, in an M. D. Anderson series including patients with cervical lymph node metastases treated with therapeutic modified neck dissection, the regional recurrence rate was 50% for patients with multiple positive lymph nodes as compared with a regional recurrence rate of only 17% when dissection was performed electively but lymph nodes were found to be involved. Other series, including patients with disease in any nodal basin, have reported regional recurrence rates ranging from 20% to 50% when dissection is performed therapeutically (Table 3).[14,27,28]
Adjuvant Radiotherapy Data
Data from several retrospective series are now available suggesting significant improvements in regional control when adjuvant nodal irradiation is delivered (Table 4).[32-38] In an analysis from M. D. Anderson, the regional recurrence rate in patients treated with adjuvant radiotherapy for axillary nodal metastases was only 13%, despite the fact that the majority of patients presented with one or more of the high-risk features outlined in Table 3. In a separate analysis, we reviewed the records of 160 patients with cervical lymph node metastases and a high risk of regional recurrence and found a 6% 10-year recurrence rate after adjuvant radiotherapy. These findings are consistent with those of other adjuvant radiotherapy series in which regional recurrence rates are consistently below what has been reported after surgery alone despite the presence of adverse clinicopathologic risk factors (compare Tables 3 and 4).
Review of published series, therefore, suggests a clear association between the risk of regional recurrence and the presence of extracapsular ex-tension, the number of involved lymph nodes, size of the lymph nodes, and the site of disease. Although no series has directly analyzed regional recurrence rates according to disease presentation (ie, recurrence after prior lymph node dissection vs primary presentation), recurrent disease is a wellaccepted risk factor for subsequent relapse and indicates the need for radiotherapy. Although therapeutic (vs elective) dissection was associated with an increased risk of nodal recurrence in several retrospective series, at M. D. Anderson we have reserved adjuvant irradiation of lymph node basins for patients who have combinations of therapeutic dissection and other high-risk features. Indications for adjuvant regional radiotherapy are summarized in Table 2.
1. Veronesi U, Adamus J, Bandiera DC, et
al: Delayed regional lymph node dissection in
stage I melanoma of the skin of the lower extremities.
Cancer 49:2420-2430, 1982.
2. Cascinelli N, Morabito A, Santinami M,
et al: Immediate or delayed dissection of regional
nodes in patients with melanoma of the
trunk: A randomised trial. Lancet 351:793-796,
3. Balch CM, Soong S Jr, Ross MI, et al:
Long-term results of a multi-institutional randomized
trial comparing prognostic factors and
surgical results for intermediate thickness melanomas
(1.0 to 4.0 mm). Intergroup Melanoma
Surgical Trial. Ann Surg Oncol 7:87-97, 2000.
4. Sim FH, Taylor WF, Pritchard DJ, et al:
Lymphadenectomy in the management of
stage I malignant melanoma: A prospective
randomized study. Mayo Clin Proc 61:697-
5. Urist MM, Balch CM, Soong S, et al: The
influence of surgical margins and prognostic
factors predicting the risk of local recurrence
in 3445 patients with primary cutaneous melanoma.
Cancer 55:1398-1402, 1985.
6. Ames FC, Balch CM, Reintgen D: Local
recurrence and their management, in Balch CM,
Houghton AN, Milton GW, Sober AJ, Soong S,
(eds): Cutaneous melanoma, pp 287-294. Philadelphia,
J.B Lippincott Company, 1992.
7. Roses DF, Harris MN, Rigel D, et al: Local
and in-transit metastases following definitive
excision for primary cutaneous malignant
melanoma. Ann Surg 198:65-69, 1983.
8. Karakousis CP, Balch CM, Urist MM, et
al: Local recurrence in malignant melanoma:
Long-term results of the multiinstitutional randomized
surgical trial. Ann Surg Oncol 3:446-
9. Ng AK, Jones WO, Shaw JH: Analysis of
local recurrence and optimizing excision margins
for cutaneous melanoma. Br J Surg
10. Heaton KM, Sussman JJ, Gershenwald
JE, et al: Surgical margins and prognostic factors
in patients with thick (>4mm) primary
melanoma. Ann Surg Oncol 5:322-328, 1998.
11. Neades GT, Orr DJ, Hughes LE, et al:
Safe margins in the excision of primary cutaneous
melanoma. Br J Surg 80:731-733, 1993.
12. Byers RM: The role of modified neck
dissection in the treatment of cutaneous melanoma
of the head and neck. Arch Surg
13. Loree TR, Spiro RH: Cutaneous melanoma
of the head and neck. Am J Surg 158:388-
14. O’Brien CJ, Coates AS, Petersen-
Schaefer K, et al: Experience with 998 cutaneous
melanomas of the head and neck over 30
years. Am J Surg 162:310-314, 1991.
15. Fisher SR, O’Brien CJ: Head and neck
melanoma, in Balch CM, Houghton AN, Sober
AJ, Soong S, (eds): Cutaneous Melanoma,
pp 163-174. St Louis, Quality Medical Publishing
16. Kelly JW, Sagabiel RW, Calderon W, et
al: The frequency of local recurrence and
microsatellites as a guide to reexcision margins
for cutaneous malignant melanoma. Ann
Surg 200:759-763, 1984.
17. Leon P, Daly JM, Synnestvedt M, et al:
The prognostic implications of microscopic
satellites in patients with clinical stage I melanoma.
Arch Surg 126:1461-1468, 1991.
18. Egbert B, Kempson R, Sagebiel R: Desmoplastic
malignant melanoma: A clinicohistopathologic
study of 25 cases. Cancer
19. Beenken S, Byers R, Smith JL, et al:
Desmoplastic melanoma. Arch Otolaryngol
Head Neck Surg 115:374-379, 1989.
20. Smithers BM, McLeod GR, Little JH:
Desmoplastic melanoma: Patterns of recurrence.
World J Surg 16:186-190, 1992.
21. Calson JA, Dickersin GR, Sober AJ, et
al: Desmoplastic neurotropic melanoma: A
clinicopathologic analysis of 28 cases. Cancer
22. Quinn MJ, Crotty KA, Thompson JF, et
al: Desmoplastic and desmoplastic neurotropic
melanoma: Experience with 280 patients.
Cancer 83:1128-1135, 1998.
23. Payne WG, Kearney R, Wells K, et al:
Desmoplastic melanoma. Am Surg 67:1004-
24. Dickson RJ: Malignant melanoma: a
combined surgical and radiotherapeutic approach.
Am J Roentgenol 79:1063-1070, 1958.
25. Johanson CR, Harwood AR, Cummings
BJ, Quirt I: 0-7-21 radiotherapy in nodular
melanoma. Cancer 51:226-232, 1983.
26. Calabro A, Singletary SE, Balch CM:
Patterns of relapse in 1001 consecutive patients
with melanoma nodal metastases. Arch Surg
27. Lee RJ, Gibbs JF, Proulx GM, et al:
Nodal basin recurrence following lymph node
dissection for melanoma: Implications for adjuvant
radiotherapy. Int J Radiat Oncol Biol
Phys 46:467-474, 2000.
28. Shen P, Wanek LA, Morton DL: Is adjuvant
radiotherapy necessary after positive
lymph node dissection in head and neck melanomas?
Ann Surg Oncol 7:554-559, 2000.
29. Monsour PD, Sause WT, Avent JM, et
al: Local control following therapeutic nodal
dissection for melanoma. J Surg Oncol 54:18-
30. Miller EJ, Synnestvedt M, Schultz D,
et al: Loco-regional nodal relapse in melanoma.
Surg Oncol 1:333-340, 1992.
31. Bowsher WG, Taylor BA, Hughes LE:
Morbidity, mortality and local recurrence following
regional node dissection for melanoma.
Br J Surg 73:906-908, 1986.
32. Ballo MT, Strom EA, Zagars GK, et al:
Adjuvant irradiation for axillary metastases
from malignant melanoma. Int J Radiat Oncol
Biol Phys 52:964-972, 2002.
33. Ballo MT, Bonnen MD, Garden AS, et
al: Adjuvant irradiation for cervical lymph node
metastases from melanoma. Cancer 97:1789-
34. Morris KT, Marquez CM, Holland JM,
et al: Prevention of local recurrence after surgical
debulking of nodal and subcutaneous
melanoma deposits by hypofractionated radiation.
Ann Surg Oncol 7:680-684, 2000.
35. Cooper JS, Chang WS, Oratz R, et al:
Elective radiation therapy for high-risk malignant
melanoma. Cancer J 7:498-502, 2001.
36. O’Brien CJ, Petersen-Schaefer K,
Stevens GN, et al: Adjuvant radiotherapy following
neck dissection and parotidectomy for
metastatic malignant melanoma. Head Neck
37. Corry J, Smith JG, Bishop M, et al:
Nodal radiation therapy for metastatic melanoma.
Int J Radiat Oncol Biol Phys 44:1065-
38. Burmeister BH, Smithers BM, Poulsen
M, et al: Radiation therapy for nodal disease
in malignant melanoma. World J Surg 19:369-
39. Krag DN, Meijer SJ, Weaver DL, et al:
Minimal-access surgery for staging of malignant
melanoma. Arch Surg 130:654-658,
40. Joseph E, Brobeil A, Glass F, et al: Results
of complete lymph node dissection in 83
melanoma patients with positive sentinel nodes.
Ann Surg Oncol 5:119-125, 1998.
41. Mraz-Gernhard S, Sagebiel RW,
Kashani-Sabet M, et al: Prediction of sentinel
lymph node micrometastasis by histological
features in primary cutaneous malignant
melanoma. Arch Dermatol 134:983-987,
42. Haddad FF, Stall A, Messina J, et al: The
progression of melanoma nodal metastasis is
dependent on tumor thickness of the primary
lesion. Ann Surg Oncol 6:144-149, 1999.
43. Gershenwald JE, Thompson W,
Mansfield PF, et al: Multi-institutional melanoma
lymphatic mapping experience: the prognostic
value of sentinel lymph node status in
612 stage I and II melanoma patients. J Clin
Oncol 17:976-983, 1999.
44. Statius Muller MG, Borgstein PJ, Pijpers
R, et al: Reliability of the sentinel node procedure
in melanoma patients: analysis of failures
after long-term follow-up. Ann Surg Oncol
45. Bachter D, Michl C, Büchels H, et al:
The predictive value of the sentinel lymph node
in malignant melanomas. Recent Results Cancer
Res 158:129-136, 2001.
46. Blumenthal R, Banic A, Brand CU, et
al: Morbidity and outcome after sentinel lymph
node dissection in patients with early-stage
malignant cutaneous melanoma. Swiss Surg
47. Caprio MG, Carbone G, Bracigliano A,
et al: Sentinel lymph node detection by
lymphoscintigraphy in malignant melanoma.
Tumori 88:S43-S45, 2002.
48. Eldh J, Suurkula M, Holmstrom H: Prognosis
for localized cutaneous melanoma treated
with wide excision only, with special reference
to development of regional node metastases.
Tumori 73:51-54, 1987.
49. Balch CM: Surgical management of regional
lymph nodes in cutaneous melanoma. J
Am Acad Dermatol 3:511-524, 1980.
50. Slingluff CL, Stidham KR, Ricci WM,
et al: Surgical management of regional lymph
nodes in patients with melanoma. Experience
with 4682 patients. Ann Surg 219:120-130,
51. Harrist TJ, Rigel DS, Day CL Jr, et al:
“Microscopic satellites” are more highly associated
with regional lymph node metastases
than is primary melanoma thickness. Cancer
52. Carmichael VE, Robins RE, Wilson KS:
Elective and therapeutic regional lymph node
dissection for cutaneous malignant melanoma:
Experience of the British Columbia Cancer
Agency, 1972 to 1981. Can J Surg 35:600-604,
53. Weissmann A, Roses DF, Harris MN, et
al: Prediction of lymph node metastases from
the histologic features of primary cutaneous
malignant melanomas. Am J Dermatopathol
54. Fisher SR: Elective, therapeutic, and
delayed lymph node dissection for malignant
melanoma of the head and neck: Analysis of
1444 patients from 1970 to 1998. Laryngoscope
55. Fortner JG, Woodruff J, Schottenfeld D,
et al: Biostatistical basis of elective node dissection for malignant melanoma. Ann Surg
56. Bonnen MD, Ballo MT, Myers JN, et al:
Elective radiotherapy provides regional control
for patients with cutaneous melanoma of the
head and neck. Cancer. In press.
57. Sause WT, Cooper JS, Rush S, et al: Fraction
size in external beam radiation therapy in
the treatment of melanoma. Int J Radiat Oncol
Biol Phys 20:429-432, 1991.
58. Ang KK, Peters LJ, Weber RS, et al:
Postoperative radiotherapy for cutaneous melanoma
of the head and neck region. Int J Radiat
Oncol Biol Phys 30:795-798, 1994.
59. Ballo MT, Ang KK: Radiation therapy
for malignant melanoma. Surg Clin North Am
60. Urist MM, Maddox WA, Kennedy JE,
et al: Patient risk factors and surgical morbidity
after regional lymphadenectomy in 204
melanoma patients. Cancer 51:2152-2156,
61. Burmeister BH, Smithers BM, Davis S,
et al: Radiation therapy following nodal surgery
for melanoma: An analysis of late toxicity.
ANZ J Surg 72:344-348, 2002.
62. Hughes TM, A’Hern RP, Thomas JM:
Prognosis and surgical management of patients
with palpable inguinal lymph node metastases
from melanoma. Br J Surg 87:892-901, 2000.
63. Karakousis CP, Driscoll DL, Rose B, et
al: Groin dissection in malignant melanoma.
Ann Surg Oncol 1:271-277, 1994.
64. Kissin MW, Simpson DA, Easton D, et
al: Prognostic factors related to survival and
groin recurrence following therapeutic lymph
node dissection for lower limb malignant melanoma.
Br J Surg 74:1023-1026, 1987.
65. Reeves ME, Delgado R, Busam KJ, et
al: Prediction of nonsentinel lymph node status
in melanoma. Ann Surg Oncol 10:27-31,41